Asset 1

Discovery Life Sciences Joins Akoya Biosciences’ Global Service Provider Network To Accelerate Immuno-Oncology Research

HUNTSVILLE, Ala., May 18, 2023 /PRNewswire/ —Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, announced today that it has officially qualified as one of Akoya Biosciences’ global service providers. The qualification process evaluated Discovery’s proficiency in staining, imaging, and analysis―allowing the company to deliver comprehensive spatial imaging services to researchers across discovery, translational, and clinical research.

With this qualification, Discovery gains access to Akoya’s PhenoImager® HT workflows, which can provide insights into the tumor microenvironment (TME) with unprecedented levels of detail and cellular co-expression with spatial contexture between cell types. These new spatial imaging technologies allow Discovery to better serve its clients in immuno-oncology by dissecting the delicate and complex biological interactions between different cell types.

As a qualified provider, Discovery has received additional tools for quantitative QC of future panels and operator and autostainer consistency. The company’s pathologist-driven, CAP-accredited, CLIA-certified, and GCLP-compliant multiplex immunofluorescence (mIF) assay development program draws heavily on decades of expertise in histopathology as well as experience in virtual microscopy powered by artificial intelligence and machine learning. Akoya’s spatial imaging technologies enhance Discovery’s capabilities―offering the highest quality multiplex IF stains with superior imaging while fully customizable according to client needs.

Being qualified as a global service provider of Akoya is a significant milestone for Discovery. We are excited to leverage this technology to deliver better insights into the tumor microenvironment for our biopharma clients. With Akoya’s reliable multiplex technology, we can perform faster and higher quality analysis on a single tissue slide, helping us better understand complex disease mechanisms so our clients can develop more effective treatments.

– Christiaan Neeleman, Head of Global Tissue Biomarker Services at Discovery

About Discovery Life Sciences

Discovery Life Sciences is the company of Biospecimen and Biomarker Specialists, combining the world’s largest commercial biospecimen inventory and procurement network with preeminent multi-omic biomarker service laboratories, including genomic, tissue biomarker, proteomic, and cell-based services to accelerate new therapies supported by biomarker and companion diagnostic programs for cancer, infectious disease, and other rare and complex conditions.   

Through AllCells®, our cell and gene therapy division, we maintain the largest recallable donor pool to supply Research Use Only (RUO) and clinical-grade fresh and cryopreserved human cellular materials to support cell and gene therapy programs in any phase of development and at any scale.   

Driven by leading scientific expertise and innovative use of current technologies, the Discovery team engages with customers to rapidly overcome obstacles and obtain results to make critical research and development decisions at market-leading speed. We are Science at your Service™! For more information, visit dls.com.

Quick Links

Technologies

Development and Clinical
Trial Solutions